Azelastine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Azelastine: From Allergic Rhinitis to Rosacea Conjunctivitis
One-Sentence Summary
Azelastine is an antihistamine nasal spray originally used for allergic and vasomotor rhinitis and for allergic forms of conjunctivitis. The TxGNN model predicts it may be effective for rosacea conjunctivitis, but no clinical trials and no publications currently support this specific prediction, so it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Allergic rhinitis, vasomotor rhinitis, atopic / papillary / vernal conjunctivitis (from the knowledge graph, because the Singapore licence records contain no indication text) |
| Predicted New Indication | Rosacea conjunctivitis |
| TxGNN Prediction Score | 98.6% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for azelastine is not available in the data compiled for this report. Azelastine is generally known as an H1-receptor antagonist with mast cell-stabilizing and anti-inflammatory effects. These properties could plausibly relieve ocular surface inflammation, which is why the model links it to conjunctivitis-type diseases.
The relationship to the original indications is only partial. Azelastine is already used for allergic conjunctivitis, so a high graph-based score for a related eye condition is not surprising. Rosacea-associated conjunctivitis, however, is driven mainly by meibomian gland dysfunction, innate immune activation and microbial factors rather than by histamine. An antihistamine may relieve symptoms at most, and there is no direct evidence that it modifies this disease. The mechanistic link is therefore unsupported.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
Both registrations are valid, single-ingredient products from the same manufacturer. No approved indication text is recorded for either.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| SIN15255P | DYMISTA NASAL SPRAY | Spray, metered | Cipla Limited |
| SIN15256P | SYNAZE NASAL SPRAY | Spray, metered | Cipla Limited |
Both products are nasal sprays. No ophthalmic formulation is registered in Singapore, so there is currently no local product suited to an eye indication.
Safety Considerations
- Contraindication signals from the knowledge graph (not taken from product label text): kidney disease and pyoureter.
- Drug Interactions: 87 potential interacting drugs were identified, but none has a severity grading. Examples include epinephrine, acetylsalicylic acid, omeprazole, pantoprazole, metformin, simvastatin, rosuvastatin, clarithromycin, prednisone, dexamethasone, budesonide and bupropion.
Please refer to the package insert for label warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high (98.6%), but there are no trials, no literature and no convincing mechanistic link between a histamine-blocking drug and rosacea conjunctivitis. Evidence is at L5 (model prediction only). Neither registered Singapore product is an eye formulation.
Other predictions for this drug:
- Allergic urticaria (L4, Hold): the evidence is only class-level reviews of H1 antihistamines. No azelastine-specific efficacy was shown, and systemic exposure from a topical product is uncertain.
- Conjunctivitis, unspecified (L1 by trial count): this is not a true repurposing signal. The supporting Phase 3 trial (NCT06212973) and several RCTs concern allergic conjunctivitis, which is already an approved indication. Azelastine may also have been only the active comparator in that Phase 3 trial.
- Other conjunctivitis subtypes (viral, parasitic, pseudomembranous, follicular, serous, Angelucci syndrome): prediction only, with poor mechanistic fit and no evidence.
To proceed, the following is needed:
- Detailed mechanism of action data (MOA)
- Evidence that histamine or mast cells contribute to rosacea conjunctivitis, for example preclinical or small exploratory clinical studies
- Information on ophthalmic formulation and route compatibility, since only nasal sprays are registered in Singapore
- Label-based warnings and contraindications from the package insert
- Severity grading of the identified drug interactions
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.